Paula J. Andryuk

Statistics

Publications

Citations

1.1K

H-Index

Active since

1994

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

American Nephrology Nurses Association

Dallas Diabetes Research Center

Paula J. Andryuk is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in glycemic control, diabetes pharmacotherapy, and medicine.

Publications per year

1994–2017

Publications

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Julio Rosenstock, Ronald Brazg, Paula J. Andryuk et al. · Clinical Therapeutics · 2006 · 516 citations

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Tina Vilsbøll, Julio Rosenstock, H Yki-Järvinen et al. · Diabetes Obesity and Metabolism · 2009 · 305 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Three distinct human thymopoietins are derived from alternatively spliced mRNAs.

Crafford A. Harris, Paula J. Andryuk, Scott W. Cline et al. · Proceedings of the National Academy of Sciences · 1994 · 111 citations

Life Sciences, Immunology, Molecular Biology +16

Structure and Mapping of the Human Thymopoietin (TMPO) Gene and Relationship of Human TMPO β to Rat Lamin-Associated Polypeptide 2

Crafford A. Harris, Paula J. Andryuk, Scott W. Cline et al. · Genomics · 1995 · 88 citations

Life Sciences, Genetics, Molecular Biology +6

Glucagon receptor antagonism induces increased cholesterol absorption

Hong-Ping Guan, Xiaodong Yang, Ku Lu et al. · Journal of Lipid Research · 2015 · 76 citations · Full text

Medicine, Endocrinology, Pharmacology +17

1–5 of 6